SIGNAL™ · Original training case · August 2026

Case 001: The PK Window Problem

Three oncology sites report pharmacokinetic (PK) collections outside the protocol window. Should the sponsor change visit planning at the affected sites or investigate further?

Prototype using fictional data only. Non-validated demo — not for real trial data. Use this page for the Case 001 site IDs, sponsor decision, and comparison counts.

The first decision

What would you verify at Site 017?

In this fictional Phase II oncology study, the monitoring report flags two collections as late. Site 017 uses a scheduled courier pickup. Choose an option to see how the monitoring lead would investigate.

Verify when the samples were collected

Start here. Compare the protocol-defined window with the actual collection timestamps. Then review processing and courier handoff separately so you can identify which step fell outside its expected window.

Ask the site to retrain its team

Retraining may help once the visit workflow is understood. First check the collection records and walk through the lab instructions with the site. A process shared by several sites would require a wider response.

Escalate the courier schedule as the cause

Test that explanation by checking the handoff times against the collection records. A shared pickup schedule gives the study team something to investigate. The collection record establishes when the draw happened.

The sponsor handoff

What should the sponsor approve?

01 / EVIDENCE

Separate facts from hypotheses

Link all three site findings. Compare the lab-manual wording with how visits were planned around courier cutoffs. Both are plausible explanations and need checking against the site records.

02 / DECISION

Give the sponsor a specific action

The fictional sponsor approves a timed PK check in visit planning at the three affected sites. The monitoring lead owns the checklist update and confirms it with each site before the next review period.

03 / FOLLOW-UP

Define the check before acting

Agree on two comparable four-week windows and use the same eligibility definition. Set the example criterion at no more than one out-of-window collection in the next 24 eligible collections.

Action status · Fictional example

Implemented · Effectiveness review pending

The monitoring lead confirms the checklist update with all three sites. The effectiveness review stays open until the lead brings the next four-week comparison to the sponsor. The sponsor then decides whether to continue monitoring or revisit the action.

Fictional Case 001 follow-up

Did the timing issue recur?

Compare scheduled, timed PK collections with an evaluable collection timestamp at the same three sites.

SiteBaseline out of windowFollow-up out of window
0172 of 80 of 8
0242 of 81 of 8
0311 of 80 of 8
All three sites5 of 24 (20.8%)1 of 24 (4.2%)

The fictional follow-up met the agreed criterion. The sponsor chose to continue monitoring. With fewer than 24 eligible collections, the review would stay open. With more than one out-of-window collection, the sponsor would revisit the action. These simulated counts illustrate the decision process.

For oncology clinical operations teams

Where does your team lose time on recurring findings?

If your lead has to assemble the evidence across reports, chase decision owners, or piece together whether an action held, bring one recurring issue to a scoping conversation. We’ll discuss the reports, sites, decisions, and follow-up checks that could fit a 90-day managed monitoring pilot.

Share the general oversight issue. Keep confidential protocol details and participant information out of the inquiry.